Novonesis A S (NVZMF) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you very much, operator, and welcome everyone to Novo Nessis conference call for the first half of 2026. As mentioned, my name is Tobias Bjorklund. I'm heading up investor relations here at Novo Nessis. In this call, our CEO, Ester Baiget, and our CFO, Rainer Lehmann, will review our performance as well as the outlook for 2026. The conference call will take around 50 minutes, including Q&A. Please change to the next slide. As usually, I would like to remind you that the information presented during the call is unaudited and that management may make forward-looking statements. These statements are based on current expectations and beliefs and involve risks and uncertainties that could cause actual results to differ materially from those described in any forward-looking statement. With that, I now have the pleasure to hand you over to our CEO, Ester Baiget. Ester, please. Thank you. Thank you, Tobias, and welcome everyone. Thank you for joining us this morning. We delivered a strong 8% organic sales growth in the first half of the year. This includes a negative effect of around 1.5 percentage points from exiting certain countries. Price contributed close to 2 percentage points and sales synergies contributed a good 1 percentage point. Growth was broad-based across all sales areas and we achieved an adjusted EBITDA margin of 37.7%. Both developed and emerging markets grew 8% in the first half of the year, with growth across all regions. We continue to deliver growth through innovation and stronger market presence with tailored solutions. We launched 11 new biosolutions and we are on track of our full year expectation of more than 30. These launches are responding to increasing needs for healthier products, higher yields, resilient and efficient production, as well...